What dosage and injection schedule should be used for intralesional triamcinolone acetonide in keloid treatment?

Intralesional Triamcinolone Acetonide for Keloid Treatment

For keloid treatment, use triamcinolone acetonide 40 mg/mL injected intralesionally into the keloid tissue, administered every 3-4 weeks. 1

Dosing Protocol

Standard Concentration and Volume

• Triamcinolone acetonide 40 mg/mL (TAC-40) is the recommended concentration for keloids and hypertrophic scars 1
• Inject 0.05-0.1 mL per injection site, which produces treatment effect over approximately 0.5 cm diameter 1
• The corticosteroid should be injected just beneath the dermis in the upper subcutis 1

Alternative Dosing Considerations

• Lower concentrations of 5-10 mg/mL triamcinolone acetonide may be used for smaller or thinner lesions to minimize atrophy risk 1
• Some evidence suggests 7.5 mg/cm² may provide good results with fewer side effects compared to 15 mg/cm² 2
• Up to 20 mg/mL can be used for localized nonresponding or very thick lesions 1

Injection Schedule

Administer injections every 3-4 weeks 1

Alternative schedules reported in the literature include:

• Monthly injections until adequate response 1
• Every 2 weeks for more aggressive treatment 3
• Every 3 weeks as used in recent clinical trials 4

Treatment Duration and Response

• Continue treatment until maximum response is achieved 1
• Most acne nodules flatten within 48-72 hours when using this technique for inflammatory lesions 1
• For keloids, treatment effects typically last approximately 9 months 1
• Multiple injection sessions are usually required for optimal results 4, 5, 3

Combination Therapy Considerations

Combining triamcinolone acetonide with 5-fluorouracil (5-FU) provides superior efficacy with fewer side effects compared to triamcinolone alone 5, 3, 6

When using combination therapy:

• Mix 0.1 mL of TAC 40 mg/mL with 0.9 mL of 5-FU 50 mg/mL 6
• Alternatively, use TAC 20 mg/mL combined with 5-FU 25 mg/mL 3
• This combination shows good to excellent response in 95% of cases versus 70% with TAC alone 5
• The combination demonstrates faster response rates and reduced complications including less atrophy and telangiectasia 5, 3, 6

Critical Safety Considerations and Adverse Effects

Common Local Complications

• Skin atrophy is the most consistent side effect, particularly with higher concentrations 1
• Telangiectasia development occurs in up to 37% of patients receiving TAC alone 6
• Pigmentary changes and hypertrichosis may occur 1
• Pain at injection site is common and limits the number of injections per session 1

Minimizing Adverse Effects

• Use lower concentrations (5-10 mg/mL) and smaller volumes (0.05-0.1 mL per site) to reduce atrophy risk 1
• Inject just beneath the dermis rather than deeper to optimize efficacy while minimizing systemic absorption 1
• Consider combination therapy with 5-FU which shows reduced complication rates 5, 3, 6

Contraindications

• Active infection at injection site (impetigo, herpes) 1
• Previous hypersensitivity to triamcinolone 1
• Active tuberculosis or systemic fungal infection (for large injections) 1
• Uncontrolled diabetes, heart failure, or severe hypertension 1

Practical Administration Tips

• Multiple injections may be given in a single session, with patient discomfort being the primary limiting factor 1
• Needleless injection devices (e.g., Dermajet) can be used as an alternative delivery method 1
• The injection volume varies based on lesional size and affected area 1
• For optimal results, ensure even distribution throughout the keloid tissue 1